{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:41:04Z","timestamp":1785516064986,"version":"3.56.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000735","name":"University of Cambridge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>ANCA-associated vasculitis (AAV) is a systemic, potentially organ and life threatening chronic autoimmune disease. With current management strategies, such as high-dose glucocorticoids in combination with cyclophosphamide or rituximab, outcomes have progressively improved with overall remission rates of 70\u201390%. However, relapse rates after discontinuation of therapy are consistently high, and treatment-related toxicity, mainly driven by glucocorticoids, still determines morbidity and quality of life. Prevention of relapses while minimizing adverse events is a major goal of long-term treatment, but the optimal duration of maintenance therapy and the role and utility of glucocorticoids in this context remains controversial. This review of induction and maintenance treatment of AAV aims to offer practical advice on immunosuppressive therapies and patient care, addressing individual risk factors and their therapeutic implications. It will discuss benefits and harms of the use of glucocorticoids, particularly focusing on recent advances in steroid sparing concepts.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaa035","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T20:10:44Z","timestamp":1579810244000},"page":"iii60-iii67","source":"Crossref","is-referenced-by-count":20,"title":["Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis"],"prefix":"10.1093","volume":"59","author":[{"given":"Irmgard","family":"Neumann","sequence":"first","affiliation":[{"name":"Vasculitis.at, Vienna, Austria"},{"name":"IZZ, Immunologiezentrum Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"2020042913161177400_keaa035-B1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","article-title":"Small-vessel vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N Engl J Med"},{"key":"2020042913161177400_keaa035-B2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1523-1755.1998.00807.x","article-title":"Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis for the EC\/BCR project for ANCA assay standardisation","volume":"53","author":"Hagen","year":"1998","journal-title":"Kidney Int"},{"key":"2020042913161177400_keaa035-B3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","article-title":"Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome","volume":"143","author":"Sable-Fourtassou","year":"2005","journal-title":"Ann Intern Med"},{"key":"2020042913161177400_keaa035-B4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation andmanagement","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J IntMed"},{"key":"2020042913161177400_keaa035-B5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"2020042913161177400_keaa035-B6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2020042913161177400_keaa035-B7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann InternMed"},{"key":"2020042913161177400_keaa035-B9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM197104292841703","article-title":"Cyclophosphamide therapy in Wegener\u2019s granulomatosis","volume":"284","author":"Novack","year":"1971","journal-title":"N Engl J Med"},{"key":"2020042913161177400_keaa035-B10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"2020042913161177400_keaa035-B11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"EUVAS (European Vasculitis Study Group): pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"2020042913161177400_keaa035-B12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200201000-00002","article-title":"Polyarteritis nodosa and Churg-Strauss angiitis: characteristics and outcome in 38 patients over 65 years","volume":"81","author":"Mouthon","year":"2002","journal-title":"Medicine"},{"key":"2020042913161177400_keaa035-B14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizingvasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020042913161177400_keaa035-B15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020042913161177400_keaa035-B16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2020042913161177400_keaa035-B17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"RAVE-ITN Research Group: rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2020042913161177400_keaa035-B18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"European Vasculitis Study Group: rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2020042913161177400_keaa035-B19","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020042913161177400_keaa035-B20","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2020042913161177400_keaa035-B21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B22","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semarthrit.2015.02.005","article-title":"Rituximab for remission induction in elderly patients with ANCA-associated vasculitis","volume":"45","author":"Timlin","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2020042913161177400_keaa035-B24","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/03009742.2012.739638","article-title":"Rituximab for ANCA-associated vasculitis in the setting of severe infection","volume":"42","author":"Gregersen","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"2020042913161177400_keaa035-B26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020042913161177400_keaa035-B27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculiti","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2020042913161177400_keaa035-B28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2020042913161177400_keaa035-B29","first-page":"260","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B30","article-title":"Outcomes in elderly patients with ANCA-associated glomerulonephritis","volume":"58(Suppl 2","author":"Liebowitz","year":"2019","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2020042913161177400_keaa035-B32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"key":"2020042913161177400_keaa035-B33","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"European Vasculitis Study Group: randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2020042913161177400_keaa035-B34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"EuropeanVasculitis Study Group (EUVAS): long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"key":"2020042913161177400_keaa035-B35","article-title":"The effect of plasma exchange on end-stage renal disease and death patients with severe ANCA-associated vasculitis","volume":"58(Suppl 2","author":"Walsh","year":"2019","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials","volume":"54","author":"Robson","year":"2015","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B37","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B39","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/keq351","article-title":"Mortality in Wegener\u2019s granulomatosis: a bimodal pattern","volume":"50","author":"Luqmani","year":"2011","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B41","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.2008.088302","article-title":"Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients","volume":"68","author":"Charlier","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020042913161177400_keaa035-B44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"2020042913161177400_keaa035-B45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2018.01.013","article-title":"Reducing glucocorticoid duration in ANCA-associated vasculitis: a pilot trial","volume":"48","author":"Miloslavsky","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2020042913161177400_keaa035-B46","article-title":"Long-term follow up of a glucocorticoid-minimizing regimen forremission-induction in ANCA-associated vasculitis","volume":"58(Suppl 2","author":"McAdoo","year":"2019","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B47","article-title":"The effect of reduced-dose oral glucocorticoids during induction of remission induction in severe ANCA-associated vasculitis","volume":"58(Suppl 2","author":"Walsh","year":"2019","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B48","doi-asserted-by":"crossref","first-page":"e0164646","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS One"},{"key":"2020042913161177400_keaa035-B49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2020042913161177400_keaa035-B50","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/ki.2013.24","article-title":"Antineutrophil cytoplasm antibody-associated vasculitis: recent developments","volume":"84","author":"Furuta","year":"2013","journal-title":"Kidney Int"},{"key":"2020042913161177400_keaa035-B51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1681\/ASN.2013101043","article-title":"With complements from ANCA mice","volume":"25","author":"Kettritz","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2020042913161177400_keaa035-B52","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2020042913161177400_keaa035-B53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/key260","article-title":"Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome","volume":"58","author":"Wester Trejo","year":"2019","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B54","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020042913161177400_keaa035-B55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"2020042913161177400_keaa035-B56","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B57","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"2020042913161177400_keaa035-B58","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2020042913161177400_keaa035-B59","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B60","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a metaanalysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2020042913161177400_keaa035-B61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020042913161177400_keaa035-B62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis: a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2020042913161177400_keaa035-B64","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","article-title":"Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts","volume":"58","author":"Pagnoux","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020042913161177400_keaa035-B65","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/rheumatology\/kex001","article-title":"Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate","volume":"56","author":"Salmela","year":"2017","journal-title":"Rheumatology"},{"key":"2020042913161177400_keaa035-B66","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/rheumatology\/kex281","article-title":"Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data","volume":"56","author":"de Joode","year":"2017","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_3\/iii60\/33145861\/keaa035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_3\/iii60\/33145861\/keaa035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T18:46:15Z","timestamp":1588185975000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/Supplement_3\/iii60\/5826905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":66,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2020,4,29]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa035","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,4,29]]}}}